A U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck & Co failed to warn that its osteoporosis ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to ...

Merck ( MRK 0.53%) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in ...

Merck (NYSE:MRK) announced Saturday that its anti-PD-1 therapy Keytruda (pembrolizumab) as part of a combination regimen ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...